BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

670 related articles for article (PubMed ID: 31473583)

  • 21. The prognostic influence of intrapancreatic tumor location on survival after resection of pancreatic ductal adenocarcinoma.
    Ruess DA; Makowiec F; Chikhladze S; Sick O; Riediger H; Hopt UT; Wittel UA
    BMC Surg; 2015 Nov; 15():123. PubMed ID: 26615588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of extent of pancreatic and venous resection on survival for patients with pancreatic cancer.
    Serenari M; Ercolani G; Cucchetti A; Zanello M; Prosperi E; Fallani G; Masetti M; Lombardi R; Cescon M; Jovine E
    Hepatobiliary Pancreat Dis Int; 2019 Aug; 18(4):389-394. PubMed ID: 31230959
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patients with resectable pancreatic adenocarcinoma: A 15-years single tertiary cancer center study of laparotomy findings, treatments and outcomes.
    Gilabert M; Turrini O; Ewald J; Moureau-Zabotto L; Poizat F; Raoul JL; Delpero JR
    Surg Oncol; 2018 Dec; 27(4):619-624. PubMed ID: 30449481
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Upregulation of CD20 Positive B-Cells and B-Cell Aggregates in the Tumor Infiltration Zone is Associated with Better Survival of Patients with Pancreatic Ductal Adenocarcinoma.
    Brunner M; Maier K; Rümmele P; Jacobsen A; Merkel S; Benard A; Krautz C; Kersting S; Grützmann R; Weber GF
    Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32150869
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Perioperative cytokine levels portend early death after pancreatectomy for ductal adenocarcinoma.
    Lewis HL; Chakedis JM; Talbert E; Haverick E; Rajasekera P; Hart P; Bloomston M; Dillhoff M; Pawlik TM; Guttridge D; Schmidt CR
    J Surg Oncol; 2018 May; 117(6):1260-1266. PubMed ID: 29205349
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pancreatic volume is one of the independent prognostic factors for resectable pancreatic ductal adenocarcinomas.
    Fukumoto T; Watanabe T; Hirai I; Kimura W
    J Hepatobiliary Pancreat Sci; 2016 Aug; 23(8):472-9. PubMed ID: 27246905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades.
    Winter JM; Brennan MF; Tang LH; D'Angelica MI; Dematteo RP; Fong Y; Klimstra DS; Jarnagin WR; Allen PJ
    Ann Surg Oncol; 2012 Jan; 19(1):169-75. PubMed ID: 21761104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Perioperative blood transfusions and survival in resected pancreatic adenocarcinoma patients given multimodality therapy.
    Newhook TE; Prakash LR; Soliz J; Hancher-Hodges S; Speer BB; Wilks JA; Bruno ML; Dewhurst WL; Arvide EM; Maxwell JE; Ikoma N; Kim MP; Lee JE; Katz MHG; Tzeng CD
    J Surg Oncol; 2021 Dec; 124(8):1381-1389. PubMed ID: 34398988
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Impact of Tumor Location on Resection and Survival for Pancreatic Ductal Adenocarcinoma.
    Winer LK; Dhar VK; Wima K; Morris MC; Lee TC; Shah SA; Ahmad SA; Patel SH
    J Surg Res; 2019 Jul; 239():60-66. PubMed ID: 30802706
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Significance of pulmonary resection in patients with metachronous pulmonary metastasis from pancreatic ductal adenocarcinoma: a retrospective cohort study.
    Mashiko T; Nakano A; Masuoka Y; Yamamoto S; Ozawa S; Nakagohri T
    BMC Surg; 2021 May; 21(1):237. PubMed ID: 33952223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
    Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
    Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The indolent nature of pulmonary metastases from ductal adenocarcinoma of the pancreas.
    Downs-Canner S; Zenati M; Boone BA; Varley PR; Steve J; Hogg ME; Zureikat A; Zeh HJ; Lee KK
    J Surg Oncol; 2015 Jul; 112(1):80-5. PubMed ID: 26153355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma - A pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials.
    Kurreck A; Weckwerth J; Modest DP; Striefler JK; Bahra M; Bischoff S; Pelzer U; Oettle H; Kruger S; Riess H; Sinn M
    Eur J Cancer; 2021 Jun; 150():250-259. PubMed ID: 33940349
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The canary in the coal mine: the growth of patient-derived tumorgrafts in mice predicts clinical recurrence after surgical resection of pancreatic ductal adenocarcinoma.
    Thomas RM; Truty MJ; Kim M; Kang Y; Zhang R; Chatterjee D; Katz MH; Fleming JB
    Ann Surg Oncol; 2015; 22(6):1884-92. PubMed ID: 25404477
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma.
    Maire F; Hammel P; Terris B; Paye F; Scoazec JY; Cellier C; Barthet M; O'Toole D; Rufat P; Partensky C; Cuillerier E; Lévy P; Belghiti J; Ruszniewski P
    Gut; 2002 Nov; 51(5):717-22. PubMed ID: 12377813
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
    Distler M; Pilarsky E; Kersting S; Grützmann R
    Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implications of the Pattern of Disease Recurrence on Survival Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma.
    Groot VP; Gemenetzis G; Blair AB; Ding D; Javed AA; Burkhart RA; Yu J; Borel Rinkes IH; Molenaar IQ; Cameron JL; Fishman EK; Hruban RH; Weiss MJ; Wolfgang CL; He J
    Ann Surg Oncol; 2018 Aug; 25(8):2475-2483. PubMed ID: 29948425
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The predictive value and role of stromal tumor-infiltrating lymphocytes in pancreatic ductal adenocarcinoma (PDAC).
    Lianyuan T; Dianrong X; Chunhui Y; Zhaolai M; Bin J
    Cancer Biol Ther; 2018 Apr; 19(4):296-305. PubMed ID: 29313457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy.
    Roland CL; Katz MH; Tzeng CW; Lin H; Varadhachary GR; Shroff R; Javle M; Fogelman D; Wolff RA; Vauthey JN; Crane CH; Lee JE; Fleming JB
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S1221-8. PubMed ID: 26350371
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathological and Radiological Splenic Vein Involvement are Predictors of Poor Prognosis and Early Liver Metastasis After Surgery in Patients with Pancreatic Adenocarcinoma of the Body and Tail.
    Mizumoto T; Toyama H; Asari S; Terai S; Mukubo H; Yamashita H; Shirakawa S; Nanno Y; Ueda Y; Sofue K; Tanaka M; Kido M; Ajiki T; Fukumoto T
    Ann Surg Oncol; 2018 Mar; 25(3):638-646. PubMed ID: 29264672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.